Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 10, 2021

India’s DCGI allows use of oxygen dependence-lowering Covid-19 drug

The Drugs Controller General of India (DCGI) has granted emergency use authorisation for a new drug, 2-deoxy-D-glucose (2-DG), as adjunct therapy that can help lower supplemental oxygen dependence in moderate to severe Covid-19 patients.

The new Covid-19 drug is available in powder form and can be dissolved in water for oral administration. Credit: Miguel Á. Padriñán from Pixabay.